Skip to main content
Premium Trial:

Request an Annual Quote

Movers & Shakers: May 27, 2011

Premium

Adarza Biosystems this week appointed Heiner Dreismann and James Senall to its board of directors.

Dreismann was previously the CEO of Roche Molecular Systems and held several senior positions at Roche Diagnostics before that.

Senall is the president of High Tech Rochester, an Adarza shareholder, and is director of the Rochester Angel Network. Previously, he was managing director of business development at Greater Rochester Enterprise.


ACS Biomarker this week named Heico Breek as its CEO.

Previously, he was CEO of cardiovascular testing company Cavadis, as well as chief commercial officer at TiGenix and a general manager at Aventis.


Venture capitalist Peter Thiel this week announced the appointment of 24 Thiel fellows, each of whom will receive $100,000 over two years to pursue innovative scientific and technical projects. Among the awardees is Alexander Kiselev, whose project is to develop an inexpensive HPLC system.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.